Safety and immunogenicity of palivizumab (Synagis) administered for two seasons
D Null Jr, B Pollara, PH Dennehy… - The Pediatric …, 2005 - journals.lww.com
D Null Jr, B Pollara, PH Dennehy, J Steichen, PJ Sánchez, LB Givner, D Carlin, B Landry…
The Pediatric infectious disease journal, 2005•journals.lww.comTo evaluate the safety and immunogenicity of palivizumab, 55 children who received
palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab
(Synagis) during the subsequent year. The single child with an antipalivizumab titer of> 1/40
had no associated serious adverse events and had expected serum palivizumab trough
concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.
palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab
(Synagis) during the subsequent year. The single child with an antipalivizumab titer of> 1/40
had no associated serious adverse events and had expected serum palivizumab trough
concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.
Abstract
To evaluate the safety and immunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of> 1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.
Lippincott Williams & Wilkins